A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
18 Years
N/A
Both
Advanced Melanoma, Cancer
Trial Information
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
The Study Drug:
Tesetaxel is designed to block cancer cells from dividing, which may cause them to die.
Screening Tests:
Signing this consent form does not mean that you will be able to take part in this study.
You will have "screening tests" to help the doctor decide if you are eligible to take part
in this study. If you have recently had any of these tests or procedures, the study doctor
may decide that you do not need to repeat them. The following tests and procedures will be
performed within 28 days before your first dose of study drug:
- Your medical history, including any side effects you may have had and any drugs you
have taken or may be taking, will be recorded.
- You will have a physical exam, including measurement of your height and weight.
- You will be asked about whether you are able to swallow capsule forms of drug.
- You will have a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan
of the head to check for brain metastasis.
- You will have a CT scan of the chest, stomach, and hip areas.
- Photographs of any melanoma on your skin will be taken. Your private areas will be
covered (as much as possible), and a picture of your face will not be taken unless
there are lesions on your face.
The following tests and procedures will be performed within 7 days before your first dose of
study drug:
- Your medical history, including any side effects you may have had and any drugs you may
be taking, will be recorded.
- You will be asked how well you are able to perform the normal activities of daily
living (performance status).
- Blood( about 2 teaspoons) will be drawn for routine tests and to test how long it takes
your blood to clot.
- Urine will be collected for routine tests.
- You will have an electrocardiogram (ECG -- a test that measures the electrical activity
of the heart).
- Women who are able to become pregnant must have a negative blood (about 1 teaspoon)
pregnancy test.
The study doctor will discuss the screening test results with you. If the screening tests
show that you are not eligible to take part in the study, you will not be enrolled. Other
treatment options will be discussed with you.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will take tesetaxel capsules
in the morning with water on Day 1 of each 21-day study cycle. You will not be allowed to
eat or drink anything except water from midnight the night before the dose until 4 hours
after taking tesetaxel.
Before you take tesetaxel, you will receive drugs to prevent nausea and vomiting. The study
doctor will discuss this with you. If you have a rash or allergic reaction, you may be
receive an antihistamine and/or corticosteroid. If you develop a low number of white blood
cells or red blood cells, you may be given growth factor drugs or receive transfusions.
These drugs may be given by mouth or vein.
Study Visits:
On Day 1 of all Cycles:
-Your medical history, including any side effects you may have had and any drugs you may be
taking, will be recorded.
On Day 9 (+/- 1 day) and again on Day 20 (+/- 2 days) of all Cycles:
- Any side effects you may have had and any drugs you may be taking will be recorded.
- Blood (about 2 teaspoons) will be drawn for routine tests.
Within 5 days before the start of cycles 3, 5, 7 and every other cycle thereafter:
- You will have a CT scan of the chest, stomach, and hip areas.
- Photographs of any melanoma on your skin will be taken.
- Any side effects you may have had and any drugs you may be taking will be recorded.
After the last dose of tesetaxel, blood (about 2 teaspoons) will be drawn for routine tests.
Within 3 weeks after the last dose of tesetaxel:
- You will have a CT scan of the chest, stomach, and hip areas.
- Photographs of any melanoma on your skin will be taken.
- Any side effects you may have had and any drugs you may be taking, will be recorded.
Length of Study:
You may continue taking the study drug for as long as the doctor thinks it is in your best
interest. You will no longer be able to take the study drug if the disease gets worse or
intolerable side effects occur.
Follow-Up Visits:
If the melanoma does not get worse while you are on study, you will have visits every 2
months for up to 12 months after your first dose of study drug. At these visits:
- You will have a CT scan of the chest, stomach, and hip areas.
- Photographs of any melanoma on your skin will be taken.
- Any side effects you may have had and any drugs you may be taking, will be recorded.
- You will be asked about any treatment you may be receiving.
If the disease gets worse while you are on study, you will have follow up phone calls every
2 months for up to 12 months after your first dose of study drug. During these calls, you
will be asked how you are feeling and about any therapy you are receiving. These calls
should take about 5 minutes.
Additional Information:
- You cannot consume beverages or foods containing grapefruit for at least 2 weeks before
the first dose of tesetaxel until 2 weeks after the last dose of tesetaxel.
- You also will not be allowed to receive any other anticancer treatments while receiving
tesetaxel.
- It is important that you provide complete and accurate information about your medical
history and any drugs you are taking or have taken in the past. False, misleading, or
incomplete information could have a serious effect on your health.
This is an investigational study. Tesetaxel is not FDA approved or commercially available.
It is currently being used for research purposes only.
Up to 27 patients will take part in this study. All will be enrolled at M. D. Anderson.
Inclusion Criteria:
1. At least 18 years of age.
2. Histologically confirmed diagnosis of melanoma.
3. Progressive disease that is not surgically resectable, or metastatic Stage IV
disease.
4. Measurable disease.
5. Serum LDH
6. Eastern Cooperative Oncology Group performance status 0 or 1.
7. Treatment with 1 prior regimen (including cytotoxic chemotherapy, immunotherapy,
radiation therapy, or cytokine, biologic, or vaccine therapy) as first-line treatment
for metastatic disease. (Administration of interleukin-2 or interferon as adjuvant
therapy is allowed and is not to be considered in determining the 1 prior treatment
regimen administered as first-line treatment for metastatic disease.)
8. Adequate bone marrow, hepatic, and renal function, as evidenced by: a) Absolute
neutrophil count (ANC) >/= 1500/mm^3; b) Platelet count >/= 100,000/mm^3; c)
Hemoglobin >/= 9 g/dL without need for hematopoietic growth factor or transfusion
support; d) Aspartate aminotransferase (AST) liver metastasis, the presence of liver metastasis,
9. (Continued # 8) g) Alkaline phosphatase metastasis, Serum creatinine /= 3.0 g/dL; j) Prothrombin time
(PT) thromboplastin time (PTT)
10. At least 3 weeks and recovery from effects of prior surgery or other therapy with an
approved or investigational agent.
11. Ability to swallow an oral solid-dosage form of medication.
12. A negative serum pregnancy test within 7 days prior to the first dose of study
medication in women of childbearing potential (that is, all women except for those
who are post menopause for > 1 year or who have a history of hysterectomy or surgical
sterilization).
13. Agreement to use a highly effective form of contraception (ie, one that has a failure
rate of < 1%) throughout the treatment phase of the study in women of childbearing
potential (that is, all women excluding those who are post menopause for > 1 year or
who have a history of hysterectomy or surgical sterilization) and sexually active men
14. Written informed consent and authorization to use and disclose health information.
15. Ability to comprehend and to comply with the requirements of the study.
Exclusion Criteria:
1. At least 18 years of age.
2. Histologically confirmed diagnosis of melanoma.
3. Progressive disease that is not surgically resectable, or metastatic Stage IV
disease.
4. Measurable disease.
5. Serum LDH
6. Eastern Cooperative Oncology Group performance status 0 or 1.
7. Treatment with 1 prior regimen (including cytotoxic chemotherapy, immunotherapy,
radiation therapy, or cytokine, biologic, or vaccine therapy) as first-line treatment
for metastatic disease. (Administration of interleukin-2 or interferon as adjuvant
therapy is allowed and is not to be considered in determining the 1 prior treatment
regimen administered as first-line treatment for metastatic disease.)
8. Adequate bone marrow, hepatic, and renal function, as evidenced by: a) Absolute
neutrophil count (ANC) >/= 1500/mm^3; b) Platelet count >/= 100,000/mm^3; c)
Hemoglobin >/= 9 g/dL without need for hematopoietic growth factor or transfusion
support; d) Aspartate aminotransferase (AST) liver metastasis, the presence of liver metastasis,
9. (Continued # 8) g) Alkaline phosphatase metastasis, Serum creatinine /= 3.0 g/dL; j) Prothrombin time
(PT) thromboplastin time (PTT)
10. At least 3 weeks and recovery from effects of prior surgery or other therapy with an
approved or investigational agent.
11. Ability to swallow an oral solid-dosage form of medication.
12. A negative serum pregnancy test within 7 days prior to the first dose of study
medication in women of childbearing potential (that is, all women except for those
who are post menopause for > 1 year or who have a history of hysterectomy or surgical
sterilization).
13. Agreement to use a highly effective form of contraception (ie, one that has a failure
rate of < 1%) throughout the treatment phase of the study in women of childbearing
potential (that is, all women excluding those who are post menopause for > 1 year or
who have a history of hysterectomy or surgical sterilization) and sexually active men
14. Written informed consent and authorization to use and disclose health information.
15. Ability to comprehend and to comply with the requirements of the study.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response rate (ie, the percentage of subjects with a confirmed complete or partial response)
Outcome Time Frame:
Baseline to Day 84
Safety Issue:
Yes
Principal Investigator
Agop Y. Bedikian, MD, BS
Investigator Role:
Study Chair
Investigator Affiliation:
UT MD Anderson Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
2009-0624
NCT ID:
NCT01064713
Start Date:
February 2010
Completion Date:
Related Keywords:
- Advanced Melanoma
- Cancer
- Tesetaxel
- Second-line therapy
- Metastatic melanoma
- Normal serum LDH
- Melanoma
Name | Location |
|---|---|
| UT MD Anderson Cancer Center | Houston, Texas 77030 |
